Find a Pharmacy
Vertice Login
Info banner
A significant part of the Healthesystems vision is to create a more integrated experience for our customers

Tag: drug development

11 posts found
lab image

Cebranopadol Phase 3 Trials Show Promising Results

A compound opioid/NOP receptor agonist demonstrated pain relief with a safety profile comparable to placebo.
Read More

FDA Issues Draft Guidance for the Use of AI in the Creation of Drugs and Medical Devices

The guidelines provide recommendations on using AI to demonstrate drug safety and effectiveness, and recommendations for AI-enabled medical devices.
Read More

New Drug in Development Could Help Patients with Spinal Cord Injuries

AZD1236, currently in Phase 2 trials, has shown an 80% preservation in nerve function following spinal cord injury.
Read More

Phase 2 Trials for Non-Opioid Pain Medication Deliver Promising Results

VX-548 delivered significant improvements in pain with few adverse events.
Read More

Additional Vaccine Candidate Performs Well in Clinical Trials

Phase 3 trials for NVX-CoV2373 across 30,000 people found this vaccine candidate to be safe and effective for the prevention of COVID-19.
Read More

FDA Diagnostic Testing Updates

The FDA is working to expedite the delivery of diagnostic testing for COVID-19.
Read More

COVID-19 and Clinical Trials

COVID-19 drug trials are underway, but the pandemic is disrupting clinical testing.
Read More

FDA Accepts New Drug Application for Opioid NKTR-181

NKTR-181 is supposed to offer a lower frequency of opioid side effects. But are more opioids really the solution we need to the opioid crisis?
Read More

New Developments in Migraine Medications

A new wave of drugs that suppress CGRP proteins to reduce migraines could be on the horizon.
Read More

FDA Proposes New Clinical Endpoints for Development of Opioid-Use Disorder Drugs

Drugs to treat opioid dependence could be approved under new clinical endpoints other than reducing opioid use.
Read More

FDA Approves New Opioid Prodrug, Apadaz

Apadaz oral tablets were approved for the short-term management of acute pain, at no more than 14 days of use.
Read More
lockmap-markermagnifiercrossmenuarrow-rightcross-circle